ClinicalTrials.gg
CompletedNCT00174915APEXUpdated Feb 2, 2012Results posted

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

A Phase 3 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-02-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,072
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
4th of 29
1,072 · median 109
Started
2003
with 1 other
Phase 3
10 of 29
none open now
Registered
2nd of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 4th largest by enrollment, is one of 2 that started in 2003, is one of 10 in phase 3, and was the 2nd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.

Read the detailed description

A Phase 3 Study comparing 80 mg, 120 mg or 240 mg of febuxostat, allopurinol (300 mg for those with normal renal function and 100 mg for those with impaired renal function) and placebo administered once daily in subjects with gout.

Subjects will receive treatment for 28 weeks.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Uric Acid, gout, xanthine oxidase, febuxostat, tophi
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hyperuricemia (serum urate ≥8.0 mg/dL and gout by American Rheumatism Association Criteria
  • Renal function defined as a serum creatinine level of \< 2.0 mg/dL and of > 20 milliliters per minute (mL/min) by Cockroft and Gault formula.

Exclusion criteria

Exclusion Criteria:

  • History of xanthinuria
  • Intolerance to allopurinol
  • Presence of renal calculi,
  • Alcohol intake of ≥ 14 drinks/week
  • medical condition
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,072 participants (actual)

Study arms

  • Experimental
    Febuxostat 80 mg QD

    Drug: Febuxostat

  • Experimental
    Febuxostat 120 mg QD

    Drug: Febuxostat

  • Experimental
    Febuxostat 240 mg QD

    Drug: Febuxostat

  • Active comparator
    Allopurinol QD

    Drug: Allopurinol

  • Placebo comparator
    Placebo QD

    Drug: Placebo

Interventions

  • Febuxostat 80 mg, orally, once daily for up to 28 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 120 mg, orally, once daily for up to 28 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 240 mg, orally, once daily for up to 28 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

  • Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.

  • DrugPlacebo

    Placebo, orally, once daily for up to 28 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).

    Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.

    Time frame: Last 3 visits (any last 3 visits up to week 28)

Secondary outcomes

  1. Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28

    Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 28 visit was summarized.

    Time frame: Week 28

  2. Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit

    The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected and may have differed by subject.

    Time frame: Final Visit (up to 28 weeks).

  3. Percent Change From Baseline in Serum Urate Levels at Week 28.

    Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as \[(Week 28 - baseline levels)/baseline\]\*100 and summarized.

    Time frame: Baseline and Week 28

  4. Percent Change From Baseline in Serum Urate Levels at Final Visit

    The percent change in serum urate from baseline to the Final visit was summarized. The percent change in serum urate was calculated as \[(Final visit - baseline levels)/baseline\]\*100. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.

    Time frame: Baseline and Final Visit (up to 28 weeks)

  5. Percent Change in Primary Tophus Size at Week 28, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.

    The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 28 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.

    Time frame: Baseline and Week 28

  6. Percent Change in Primary Tophus Size at Final Visit, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.

    Percent change in primary tophus size was calculated as \[(Final Visit - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.

    Time frame: Baseline and Final Visit (up to 28 weeks)

  7. Change in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.

    Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0.

    Time frame: Baseline and Week 28

  8. Change in the Total Number of Tophi at Final Visit in the Subset of Subjects With Palpable Tophi at the Screening Visit

    Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.

    Time frame: Final Visit (up to 28 weeks)

  9. Percentage of Subjects Requiring Treatment for a Gout Flare Between Weeks 8 and 28 of the Double-Blind Treatment Period.

    Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.

    Time frame: Weeks 8 through 28

07

Results

Posted Jul 16, 2009

Participant flow

Subjects were enrolled at 167 investigative sites in the United States from 21 February 2003 to 07 April 2004.

Participant flow — Overall Study
MilestoneFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Started267269134268134
Completed17420086211101
Not completed9369485733
Withdrew: Lost to follow-up191791710
Withdrew: Adverse event181611185
Withdrew: Personal reason(s)1616999
Withdrew: Other158653
Withdrew: Gout flare136810
Withdrew: Protocol violation63363
Withdrew: Therapeutic failure63213

Outcome measures

PrimaryPercentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).

Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.

Time frame:
Last 3 visits (any last 3 visits up to week 28)
Reported as:
Number · Percentage of subjects
Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).
Percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).486569220
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (The overall 0.05 level of significance for the multiple comparisons of each febuxostat dose to placebo was controlled using Hochberg's method. The p-value was statistically significant.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL versus \[v.\] \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (The overall 0.05 level of significance for the multiple comparisons of each febuxostat dose to placebo was controlled using Hochberg's method. The p-value was statistically significant.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (The overall 0.05 level of significance for the multiple comparisons of each febuxostat dose to placebo was controlled using Hochberg's method. The p-value was statistically significant.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Allopurinol QD · Difference in percentage: 25.7 · 97.5% CI 16.7 to 34.7
  • Febuxostat 120 mg QD vs Allopurinol QD · Difference in percentage: 42.7 · 97.5% CI 34.0 to 51.3
  • Febuxostat 80 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Comparisons of each febuxostat dose to allopurinol were adjusted to control the overall 0.05 level of significance for superiority by using Hochberg's method. The p-value was statistically significant.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Comparisons of each febuxostat dose to allopurinol were adjusted to control the overall 0.05 level of significance for superiority by using Hochberg's method. The p-value was statistically significant.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = 0.479 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Allopurinol QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28

Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 28 visit was summarized.

Time frame:
Week 28
Reported as:
Number · Percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28
Percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28768794411
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Cochran-Mantel-Haenszel · p = 0.011 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = 0.091 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Allopurinol QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit

The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected and may have differed by subject.

Time frame:
Final Visit (up to 28 weeks).
Reported as:
Number · Percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit
Percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit727992391
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Cochran-Mantel-Haenszel · p = 0.074 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = 0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Allopurinol QD vs Placebo QD · Cochran-Mantel-Haenszel · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
SecondaryPercent Change From Baseline in Serum Urate Levels at Week 28.

Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as \[(Week 28 - baseline levels)/baseline\]\*100 and summarized.

Time frame:
Baseline and Week 28
Reported as:
Mean · Percent change
Percent Change From Baseline in Serum Urate Levels at Week 28.
Percent changeFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percent Change From Baseline in Serum Urate Levels at Week 28.-47.6 ± 15.86-54.9 ± 14.97-67.8 ± 18.18-34.4 ± 14.21-3.6 ± 13.85
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 120 mg QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 240 mg QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 80 mg QD vs Allopurinol QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 240 mg QD vs Allopurinol QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Allopurinol QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
SecondaryPercent Change From Baseline in Serum Urate Levels at Final Visit

The percent change in serum urate from baseline to the Final visit was summarized. The percent change in serum urate was calculated as \[(Final visit - baseline levels)/baseline\]\*100. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.

Time frame:
Baseline and Final Visit (up to 28 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Serum Urate Levels at Final Visit
Percent changeFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percent Change From Baseline in Serum Urate Levels at Final Visit-45.2 ± 18.16-51.9 ± 17.99-66.3 ± 20.62-33.7 ± 14.75-3.0 ± 13.28
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 120 mg QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 240 mg QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 80 mg QD vs Allopurinol QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 240 mg QD vs Allopurinol QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
  • Allopurinol QD vs Placebo QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the ANOVA model with treatment and baseline renal function as factors. Statistical significance was determined at the 0.05 level without adjustments for multiple comparisons.)
SecondaryPercent Change in Primary Tophus Size at Week 28, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.

The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 28 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.

Time frame:
Baseline and Week 28
Reported as:
Median · percent change from baseline
Percent Change in Primary Tophus Size at Week 28, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percent Change in Primary Tophus Size at Week 28, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.-45.6 (-85.9 to 3.0)-54.2 (-100.0 to -16.7)-53.2 (-77.8 to -22.1)-31.5 (-95.0 to 5.6)-52.0 (-62.5 to -21.4)
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.789 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.320 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.381 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.809 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.154 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.247 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.415 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.649 (Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.807 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Allopurinol QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.844 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryPercent Change in Primary Tophus Size at Final Visit, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.

Percent change in primary tophus size was calculated as \[(Final Visit - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.

Time frame:
Baseline and Final Visit (up to 28 weeks)
Reported as:
Median · percent change from baseline
Percent Change in Primary Tophus Size at Final Visit, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percent Change in Primary Tophus Size at Final Visit, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.-33.8 (-85.4 to 0.0)-42.4 (-90.3 to 0.0)-47.0 (-80.0 to -13.8)-22.6 (-66.7 to 0)-40.3 (-62.5 to -16.7)
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.699 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.822 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.579 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.679 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.278 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.104 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.560 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.309 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.759 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Allopurinol QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.385 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryChange in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.

Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0.

Time frame:
Baseline and Week 28
Reported as:
Median · number of tophi
Change in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.
number of tophiFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Change in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.0.0 (-0.5 to 0.0)0.0 (-2.0 to 0.0)0.0 (-1.0 to 0.0)0.0 (-1.0 to 0.0)0.0 (0.0 to 0.0)
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.949 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.050 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.577 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.598 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.062 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.969 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.056 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.659 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.197 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Allopurinol QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.521 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryChange in the Total Number of Tophi at Final Visit in the Subset of Subjects With Palpable Tophi at the Screening Visit

Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.

Time frame:
Final Visit (up to 28 weeks)
Reported as:
Median · number of tophi
Change in the Total Number of Tophi at Final Visit in the Subset of Subjects With Palpable Tophi at the Screening Visit
number of tophiFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Change in the Total Number of Tophi at Final Visit in the Subset of Subjects With Palpable Tophi at the Screening Visit0.0 (0.0 to 0.0)0.0 (-1.0 to 0.0)0.0 (-1.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.683 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.078 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.442 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.990 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.077 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 240 mg QD vs Allopurinol QD · Wilcoxon (Mann-Whitney) · p = 0.662 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.139 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.705 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Wilcoxon (Mann-Whitney) · p = 0.337 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Allopurinol QD vs Placebo QD · Wilcoxon (Mann-Whitney) · p = 0.643 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryPercentage of Subjects Requiring Treatment for a Gout Flare Between Weeks 8 and 28 of the Double-Blind Treatment Period.

Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.

Time frame:
Weeks 8 through 28
Reported as:
Number · percentage of subjects
Percentage of Subjects Requiring Treatment for a Gout Flare Between Weeks 8 and 28 of the Double-Blind Treatment Period.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Percentage of Subjects Requiring Treatment for a Gout Flare Between Weeks 8 and 28 of the Double-Blind Treatment Period.5554574652
Statistical analysis
  • Febuxostat 80 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = 0.645 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = 0.756 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Placebo QD · Cochran-Mantel-Haenszel · p = 0.428 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = 0.076 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons..)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL)
  • Febuxostat 120 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = 0.106 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 240 mg QD vs Allopurinol QD · Cochran-Mantel-Haenszel · p = 0.069 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Cochran-Mantel-Haenszel · p = 0.837 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 80 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = 0.749 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Febuxostat 120 mg QD vs Febuxostat 240 mg QD · Cochran-Mantel-Haenszel · p = 0.581 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).
  • Allopurinol QD vs Placebo QD · Cochran-Mantel-Haenszel · p = 0.311 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)The Cochran-Mantel-Haenszel test was stratified by baseline renal function (serum creatinine ≤1.5 mg/dL v. \>1.5 mg/dL).

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 80 mg QD—11/267 (4.1%)122/267 (45.7%)
Febuxostat 120 mg QD—9/269 (3.3%)123/269 (45.7%)
Febuxostat 240 mg QD—5/134 (3.7%)72/134 (53.7%)
Allopurinol QD—7/268 (2.6%)133/268 (49.6%)
Placebo QD—2/134 (1.5%)61/134 (45.5%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Coronary Artery Disorders NECCardiac disorders2/2670/2690/1340/2681/134
Pain and Discomfort NECGeneral disorders2/2671/2690/1341/2680/134
Supraventricular ArrhythmiasCardiac disorders0/2671/2691/1340/2680/134
Abdominal Hernias, Site UnspecifiedGastrointestinal disorders0/2670/2691/1340/2680/134
Duodenal and Small Intestinal Stenosis and ObstructionGastrointestinal disorders0/2670/2691/1340/2680/134
Device Related ComplicationsInjury, poisoning and procedural complications0/2670/2690/1340/2681/134
Non-Site Specific Procedural ComplicationsInjury, poisoning and procedural complications0/2670/2690/1340/2681/134
Total Fluid Volume DecreasedMetabolism and nutrition disorders0/2670/2691/1340/2680/134
Seizures and Seizure Disorders NECNervous system disorders0/2670/2691/1340/2680/134
Renal Failure and ImpairmentRenal and urinary disorders0/2670/2691/1340/2680/134
Most frequent other events
Showing 10 of 13
Most frequent other events
EventFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QD
Upper Respiratory Tract InfectionsInfections and infestations39/26752/26927/13452/26821/134
Diarrhoea (Excluding Infective)Gastrointestinal disorders16/26719/26918/13417/26811/134
Musculoskeletal and Connective Tissues Signs and Symptoms NECMusculoskeletal and connective tissue disorders23/26724/26914/13427/26813/134
Headache NECNervous system disorders14/26714/26912/13419/2687/134
Joint Related Signs and SymptomsMusculoskeletal and connective tissue disorders17/26723/2697/13420/2687/134
Non-Site Specific Injuries NECInjury, poisoning and procedural complications11/2679/2699/1348/2683/134
Neurological Signs and Symptoms NECNervous system disorders5/2675/2699/1346/2682/134
Liver Function AnalysesInvestigations17/26710/2696/13415/2683/134
Gastrointestinal & Abdominal Pains, Excluding Oral,ThroatGastrointestinal disorders5/2677/2698/1346/2683/134
Nausea and Vomiting SymptomsGastrointestinal disorders11/26710/2698/1346/2685/134

Baseline characteristics

Age, Customized
Age, Customized(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QDTotal
<45 years8279338236312
45 years to <65 years1461547114779597
≥65 years3936303919163
Age Continuous
Age Continuous(years)Febuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QDTotal
Mean50.6 ± 12.2451.2 ± 11.5754.3 ± 12.8351.8 ± 12.2551.5 ± 12.1851.6 ± 12.17
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QDTotal
Female16138191167
Male2512561262491231005
Race/Ethnicity, Customized
Race/Ethnicity, Customized(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QDTotal
White200214107206108835
Black or African American382713339120
Hispanic13168171064
Asian8816326
Other8456427
Body Mass Index
Body Mass Index(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QDTotal
<18.5 kilogram per meter² (kg/m²)000000
18.5 kg/m² to <25 kg/m²10119151661
25 kg/m² to <30 kg/m²8581429148347
≥30 kg/m²1721768316170662
missing010102
Presence of a Primary PalpableTophus
Presence of a Primary PalpableTophus(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QDTotal
Yes4853256429219
No, but other tophi present031116
No, and no other tophi present219213108203104847
Serum Creatinine
Serum Creatinine(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat 240 mg QDAllopurinol QDPlacebo QDTotal
≤1.5 milligram per deciliter (mg/dL)2582581292581291032
>1.5 mg/dL911510540
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209. PubMed 18975369 ↗
  • Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):585-91. doi: 10.1080/15257770802136032. PubMed 18600509 ↗
  • Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008. PubMed 21353107 ↗
  • Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680. PubMed 22052584 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Feb 2003
Primary completionActual
Apr 2004
CompletionActual
Apr 2004
Results first posted
Jul 16, 2009
Last update
Feb 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174915
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Feb 2003
Primary completion
Apr 2004
Completion
Apr 2004
Results posted
Jul 16, 2009
Last update
Feb 2, 2012

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion